Introduction
Halve of the population sustains at least one fracture during their lifetime 1 , and the majority of these fractures heal successfully. Successful fracture healing requires the following five elements; (i) osteogenic cells (e.g., osteoblasts), (ii) osteoinductive stimuli (e.g., bone morphogenetic proteins); (iii) an osteoconductive matrix; (iv) adequate blood and nutrient supply, and (v) sufficient mechanical support 2 . One or more elements can be compromised due to the existence of a bone defect. Bone defects are treated with bone grafts in order to avoid insufficient fracture healing. Insufficient fracture healing is encountered in 5 to 10% of the fractures, resulting in delayed union, malunion, or non-union 3 .
Most commonly used bone graft material is autologous bone. Autologous bone is usually harvested from the iliac crest 4 . However, harvesting autologous bone lengthens the surgical procedure and is associated with complications in 8-39% of patients (e.g., infection, nerve and urethral injury, and postoperative or chronic pain) 5 . An alternative option is to use allogeneic bone. However, allogeneic bone grafting is considered suboptimal since it has biocompatibility disadvantages 6 . The disadvantages of autologous and allogeneic bone grafts have resulted in the development of alternative (synthetic) bone substitute materials. The most interesting group of bone substitute materials is probably calcium phosphate (CaP), because
CaPs mimic the mineral part of natural bone 7 .
CaP-based bone substitutes have been studied for several decades 8 and they can be categorized into CaP ceramics and CaP cements (CPC) 7 . CaP ceramics are obtained by thermal treatment (sintering), generally resulting in solid grafting materials (e.g., blocks or granules). CPCs, on the other hand, consist of CaP powder that forms a paste upon mixing with a liquid. Mixing is usually done during surgery and the resulting paste becomes solid within several minutes through an isothermic chemical setting reaction. During this setting reaction, the CPCs can be moulded by the surgeon into any desired shape in order to completely fill the defect.
Since the introduction of CPC in 1985 by Brown and Chow, a number of CPCs have become commercially available for trauma and orthopaedic surgery 9 . Trauma or orthopaedic surgeons are therefore given the opportunity to select a CPC that meets the specific demands of each bone defect that requires bone grafting. The aim of this technical note was to provide a comprehensive overview of knowledge of commonly used CPCs that may improve this selection for bone defects encountered during fracture treatment. The chemical composition and structural, mechanical and biological properties of the four predominantly used CPC products (Table 1) are discussed. In addition, the biological properties were evaluated in a large animal bone defect model. Finally, a systematic literature search was conducted in order to provide insight into the available clinical evidence supporting to use of these CPC products to graft bone defects encountered during fracture treatment.
Calcium phosphate cements
CPCs can be classified based upon the setting product of the CPC into apatite-forming and brushite-forming CPCs. This classification refers to the degree of crystallinity of the CaP formed and has a direct impact on their resorption rate. (Table 2) . CPC products are available in several quantities, ranging from 1.5 cc to 30 cc (Table 1) , and depending on the CPC product the setting reaction will take five (Calcibon 13 . Furthermore the majority of these pores is smaller than 150 µm. Average pore size of ChronOS TM Inject is 100 µm, and 18 % of these pores exceed the size of 150 µm. Average pore sizes of other apatiteCPCs is ~50 µm and the fraction that exceeds the size of 150 µm is less than 4 %.
Mechanical properties
The mechanical properties of a bone substitute material should ideally be comparable to the bone being replaced. However, the mechanical properties of bone differ according to their structure (cortical or trabecular bone) and function (weight-bearing or non-weight-bearing).
Compression strength of human cortical bone is in the range of 130 to 190 MPa, whereas trabecular bone has a compression strength of 8 to 38 MPa. Apatite-CPCs were found to have a compression strength in the range of trabecular bone ( 
Biological properties
Biological properties of four CPCs were studied in a drill-hole tibia bone defect model in goats 14 . This model allows for a direct comparison of different CPCs. Three months after grafting the drill-hole defects with different CPCs, resorption and bone formation were determined using micro-CT scanning, histology, and fluorochrome labeling (Supplementary
Materials and Methods). The study was approved by the institution's Animal Ethics
Committee (EUR1540).
The micro-CT scans acquired at three months after grafting showed that drill-hole Histology confirmed that resorption rate of apatite-CPCs is very limited and that, as a result, these CPCs remained largely intact ( Figure 2 ). Calcibon ® still covered almost the complete defect and hardly any bone ingrowth had appeared within three months. 16 . The minimal appearance of fluorochrome labels at CPC-interface of tibia defects grafted with BoneSource ® and Norian SRS ® also indicate little bone forming activity ( Figure   2 ).
Histology of the only brushite-based CPC, ChronOS TM Inject, indicated indeed that most of CPC was resorbed within three months time. This was also shown by Apelt et al., who found that only 20 % of ChronOS TM Inject was still present six months after grafting subchondral bone defects in sheep 16 . In the periphery of the defect, ChronOS TM Inject had resorbed and was replaced by new bone. After three months, only some bits of CPC were found within the center of the defect (Figure 2 ). Contrary to the limited bone forming activity found for apatite-CPCs, this brushite-CPC seemed to elect a bone formation activity almost throughout the complete CPC-interface ( Figure 2 ).
Clinical evidence in fracture treatment
A systematic literature search was conducted using the product names of all products ( All references of included manuscripts were reviewed in order to ensure that no relevant papers had been missed.
The systematic literature search resulted in seventy-eight eligible manuscripts. Thirtythree of these manuscripts were selected for final inclusion, including one additional reference (Table 4 ). The included manuscripts consisted of ten clinical trials, two case-control studies, twenty case-series and one case-report. The four CPC have been used to graft bone defects encountered in treatment of humerus, radius, femur, tibia, calcaneus, vertebra, and odontoid factures (Table 5) , as well as bone defect encountered during knee or hip revision surgery and treatment of endochondrale bone cysts.
BoneSource ® was subjected to one multicenter prospective randomized trial 17 .
Metaphyseal bone defects of thirty-eight fractures, including femur, tibia, calcaneus, humerus, and distal radius fractures were grafted with either BoneSource ® or autologous bone.
Adequate reduction was maintained in 83 % of the defects treated with BoneSource ® versus 67 % of the defect treated with autologous bone. Furthermore, reduction and injection of BoneSource ® was compared with reduction and fixation with K-wires as a treatment for displaced distal radius fractures 18 . In their study, all clinical and radiographic parameters were worse after twenty-six weeks in the BoneSource ® groups, and they concluded that (Table 3) , and may therefore be most suitable to graft defects of metaphyseal bone defect. Brushite-forming CPCs only offer minimal mechanical strength, and they should therefore only be used in situations in which sufficient mechanical stability can already be acquired using fixation hardware. Overall, CPCs do not possess sufficient mechanical strength to be used in cortical or weight-bearing bone defect.
Micro-CT data indicates that CPCs form a rather dense structure with only a limited amount of pores that may allow bone and vessel ingrowth. The working mechanism in which CPCs can support bone formation is therefore more likely based on gradual resorption of the CPC and subsequent bone formation. Resorption of CPCs is an active process mediated by osteoclasts 7 . The resorption rate is an interplay of chemical composition, structure and volume of the CPC and the availability and activity of osteoclasts. Resorption of CPC should be followed by bone formation until complete regeneration of the bone defects has occurred. The regenerative potential of the surrounding bone should therefore be taken into account, and when rapid bone formation can be expected, fast resorbing brushite-forming CPCs, such as ChronOS TM Inject, may be preferred over apatite-forming CPCs.
CPCs are mostly studied as a bone substitute material to graft metaphyseal bone defects (Table 5) . Grafted metaphyseal bone defects include fractures of the femur, tibia, calcaneus, humerus, radius, and vertebra. The majority of the studies included in the systematic literature search consist of case-series. Case-series can provide relevant knowledge about the specific indication in which a CPC can be used and the relative safety, however they are not the preferred evidence to draw well-founded conclusions on the clinical benefits of using CPCs. Furthermore, the average number of clinical studies performed with each CPC product is surprisingly low, especially for BoneSource ® , ChronOS TM Inject and Calcibon ® (Table 4) . More clinical studies, preferably randomized controlled trials, are therefore desired and can contribute to better understanding of the potential indications and benefits of different CPC products.
Limitations
There are limitations to this work. Firstly, the selection of CPC products was based upon their availability for use in trauma and orthopaedic surgery in the Netherlands. The included products are widely available and used worldwide, which supports a wide relevance of this paper. On the other side, several other CPC products such as Norian Drillable Therefore, whether metaphyseal bone defects can successfully be grafted with the studied CPC cannot be directly translated from their performance in this model. The biological properties as described here provide important clues that can help to determine which product is most suitable for each type of bone defect encountered during clinical practice. Finally, the systematic literature search may not have been able to retrieve all relevant publications of the included CPC products. This risk is minimized through performing the search with the product name as search term in two different databases (Embase and PubMed) and screening reference lists of the included articles for additional publications (one publication found).
Missing publications that did not specify the product name is not considered a limitation, since this systematic search was conducted to provide insight into the available clinical evidence of the commercially available CPC products, helping trauma and orthopaedic surgeons to select the most suitable product. Mentioning the product name was therefore essential for this study. 
Supplementary Materials and Methods

Animal experiment
In five skeletally mature female milk goats, each weighing 50-60kg, a drill-hole bone defect model was used in which three holes were created at the diaphysis of the right tibia. Two of the holes were grafted with a CPC and one was left empty, serving as a control. All products were tested in duplicate and randomized over the proximal, distal and middle holes. After three months, the goats were killed and the grafted bone defects were analyzed using micro-CT, histology, and fluorochrome labeling.
Surgical procedure
The operation was performed under general anesthesia induced by an intravenous injection of 0.3ml medetomidine (1mg/ml) followed by 20ml propofol (10mg/ml) and maintained by isoflurane 1.5% through a constant volume ventilator, administered through an endotracheal tube. The goats received prophylactic antibiotics according to the following scheme: 12.5ml amoxicillin (48mg/ml) at the start of the operation and 7.5ml ampicillin (100mg/ml) during the operation; and two and four days after the operation.
Before surgery, the animal was immobilized on its right side and the right limb was shaved, washed, and disinfected with povidone-iodine. A longitudinal incision was made on the medial surface of the tibia, and the bone was exposed by blunt dissection. Three unicortical 2.0mm diameter holes were drilled at low rotational drill speeds and continuous cooling with cold physiologic saline, with an interspace of 2.5cm. The 2.0mm diameter holes were enlarged to 5.0mm diameter and irrigated and packed with sterile cotton gauze, and the calcium phosphate cements were then prepared. Subsequently, the cements were injected into the bone defects and allowed to solidify. Any extruding material was removed. The soft tissues and skin were closed in separate layers with Vicryl sutures. Post operative analgesia consisted of 0.8ml buprenorphine (300μg/ml) and 1.0ml flunixin (50mg/ml) on day zero to three post surgery.
Fluorochrome labeling
The fluorochrome labels were administered intravenously at 14 days (tetracycline hydrochloride, 30 mg/kg (Sigma)) and four days (calcein, 10 mg/kg intravenously (Sigma)) before they were killed using an overdose pentobarbital.
Micro-CT evaluation
The right tibias were taken out and trimmed to a suitable size for micro-CT scanning. A 9 µm-resolution protocol (75 kV energy, 133 µA current, 1.0 mm Al filter) was used with a SkyScan 1076 micro-CT scanner (Bruker micro-CT N.V., Kontich, Belgium). The CT images were reconstructed using NRecon software version 1.5 (Bruker micro-CT N.V., Kontich, Belgium).
Histological evaluation
After micro-CT scanning, each tibia was trimmed to a size suitable for histological processing. Subsequently, all specimens were fixed in paraformaldehyde (4%) overnight, dehydrated in a graded series of ethanol, and embedded in methylmethacrylate (MMA). After polymerization, undecalcified thin (6μm) sections were made with a heavy duty microtome in a transverse direction through the middle of the defect area. Sections were stained using Goldner's trichrome and evaluated with a light microscope (Olympus BX50). Fluorochrome labels were evaluated in unstained sections using an epifluorescence microscope (Axiovert 200MOT/Carl Zeiss) equipped with a double filter block. 
